

COVAX

CEPI



Regional VPPEF Clinic

The AMC is an innovative finance instrument which frontloads doses to achieve equitable access to COVID-19 vaccines

Objective



Accelerating the availability of effective vaccines



Securing at least 1 billion doses by the end of 2021 for AMC eligible economies.



Making vaccines affordable

Impact



Protect health care workers and the most vulnerable populations



Help prevent the transmission of COVID-19 around the world



Help restart the world's economy by mitigating the impact of the pandemic

To achieve these we have raised \$8.7bn and are developing other financing mechanisms

COVAX pledges on the rise with US\$ 7 Bn raised to date and 100mn dose donations announced by Team Europe

Dose-sharing announcements



- France to donate 5%+ of bilaterally procured doses to COVAX in 2021, including 500k+ confirmed for delivery in May and 1M in June
- Inaugurated dose-sharing mechanism and created framework for Team Europe



- New Zealand sharing 1.6Mn of its COVAX doses in 2021
- To be delivered in June



- Sweden signed agreement to donate of one million doses via COVAX, leveraging Team Europe framework



- Spain announced it will share 5-10% of its doses via COVAX in 2021, leveraging Team Europe framework



- UAE announced donation of 1 million doses via COVAX



- Team Europe announces a combined donation of 100 million doses, includes donations shown above from France, Spain, Sweden, and others



- USA announces 80M doses to be shared, at least partially through COVAX

About shared doses

- **Dose-sharing benefits all AMC participants** by increasing the number of doses available and accelerating coverage
- Shared doses meet the **same safety and effectiveness standards** as all other COVAX doses
- They follow the **same COVAX processes**, and benefit from the same terms (e.g., I&L, no-fault compensation programme)
- Shared doses will be allocated to advance equity goals, leveraging the principles of the **Allocation Mechanism¹**
- **Countries will be notified** if they are allocated shared doses to confirm interest and ensure preparedness
- Shared doses **accelerate** recipients' COVAX coverage, and ultimately **augment** the number of total doses a recipient receives through COVAX

COVAX will soon confirm supply expectations with countries who indicated demand to purchase additional doses through cost sharing



Supply expectations

- For Participants who submitted requests for additional doses, COVAX will confirm how many it expects to be able to provide in 2021 and early 2022¹
- These doses will be additional to donor-funded doses, and will be allocated after all Participants have reached 20%



Vaccine preferences and confirmation

- Participants who commit to purchasing additional doses will indicate preferences among vaccines on offer (including any they wish to opt out of)
- Based on these preferences, COVAX will confirm which specific vaccines each Participant will receive



Financing

- Participants will be required to pay up front at time of confirmation of vaccines, in order to lock in the doses
- Participants should work with multilateral development banks (MDBs), as relevant, to confirm financing for additional COVAX doses in advance
- COVAX is working closely with MDBs to align processes for securing and disbursing financing for additional doses



Timeline and next steps

- Supply expectations and next steps for commitments to purchase doses will be communicated shortly
- Delivery of additional doses is expected to begin in Q4¹

1. Subject to supply constraints.

COVAX Facility: 6 Key Metrics



\$8.7bn raised for COVAX AMC against our 2021 target of \$8.3bn



8 vaccine candidates with signed agreements against our 2021 target of 10 candidates




1.6B doses for delivery in 2021, based on signed agreements and deals under negotiation, against our 2021 target of 2B doses for delivery in 2021**, and an estimated 0.3B doses for delivery in 2021 from dose-sharing



89% of COVAX participants* have received first shipment of doses against our June 2021 target of 100% of participants



Of 150mn doses allocated **88mn doses delivered** to COVAX economies against our 2021 target of 2B doses



962,623,815 people vaccinated against COVID-19 with at least 1 dose from all vaccine sources

COVAX specific metric and target in progress

* Of the 147 of 160 active participants who have received an allocation. 31 of the 191 confirmed and eligible participants are not active – the 27 EU member states (represented by the European Commission who is active) and the 4 non-participating AMC participants. 14 participants were not allocated doses due to opt-outs, voluntary delays and unmet financial commitments. ** Volumes at risk due to constraints in manufacturing (production levels) and supply (export controls)
 Source: Supply Forecast - <https://www.gavi.org/sites/default/files/covid/covax/COVAX%20Supply%20Forecast.pdf>; Deliveries ; # people vaccinated: <https://covid19.who.int/>

COVAX

CEPI



Thank you